Latest filing published 14 Apr 2023 for ExpreS2ion Biotech Holding AB (EXPRS2), €956.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Sara Sande: trading record in brief
Sara Sande discloses dealings in ExpreS2ion Biotech Holding AB (EXPRS2) to Finansinspektionen. Between 22 June 2022 and 12 April 2023, the trades on record add up to 2 filings.
Purchases make up the whole of the open-market record (1 purchase, €4,673). Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The latest filing, published on 14 April 2023, reports a transaction of €956 in ExpreS2ion Biotech Holding AB (EXPRS2). The most recent open-market purchase was published on 24 June 2022, 1,598 days ago. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Companies and markets linked to Sara Sande
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,220 shares@ SEK 4.9017.0% of flowBTU (betald tecknad unit)ISIN SE0019925017FI:csv-f61b50abfda96ee99156
- 4,000 shares@ SEK 12.50100.0% of flowAktieISIN SE0008348262FI:csv-554315de12d09a9a6bb4Canonical exit: 20 Sept 2022 (T+90)
2 of 2 declarations